Achromobacter xylosoxidans bacteremia: clinical and microbiological features in a 10-year case series
Open Access
- 1 June 2018
- journal article
- research article
- Vol. 31 (3) , 268-273
Abstract
Objective. The treatment of Achromobacter xylosoxidans bacteremia is challenged by antimicrobial resistance and the paucity of data. We aimed at offering a contemporary description of this uncommon entity. Patients and methods. Retrospective case series of 13 episodes of A. xylosoxidans bacteremia diagnosed over a 10-year period (November 2007 to May 2017) in our tertiary care center. Results. Solid organ cancer and heart failure were the most common comorbidities (4/13 [30.7%]). All but one episodes were hospital-acquired. Most patients had received previous antibiotic therapy (7/13 [53.8%]) and had a central venous catheter in place (6/13 [46.1%]). Primary and intravascular catheter were the most common sources (4/13 [30.7%] each). Meropenem was the agent with best in vitro activity (92.3% [12/13] of susceptible isolates). All-cause 30-day mortality (overall 23.1%) was higher in patients with primary bacteremia (50.0% vs. 11.1%; P-value=0.203) and prior chemotherapy (66.7% vs. 10.0%; P-value=0.108). Conclusions. Bacteremia due to A. xylosoxidans constitutes a serious infection among immunocompromised hosts. Carbapenem-based therapy may be appropriate in most cases.Keywords
This publication has 20 references indexed in Scilit:
- Bacteremia due to Achromobacter xylosoxidans in neonates: clinical features and outcomeThe Brazilian Journal of Infectious Diseases, 2013
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistanceClinical Microbiology and Infection, 2012
- Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2009
- Bacteremia caused by Achromobacter and Alcaligenes species in 46 patients with cancer (1989–2003)Cancer, 2004
- Antibiotic Therapy for Klebsiella pneumoniae Bacteremia: Implications of Production of Extended-Spectrum -LactamasesClinical Infectious Diseases, 2004
- Achromobacter xylosoxidans Bacteremia: A 10-Year Analysis of 54 CasesEuropean Journal of Clinical Microbiology & Infectious Diseases, 2003
- Emendation of GenusAchromobacterandAchromobacter xylosoxidans(Yabuuchi and Yano) and Proposal ofAchromobacter ruhlandii(Packer and Vishniac) Comb. Nov.,Achromobacter piechaudii(Kiredjian et al.) Comb. Nov., andAchromobacter xylosoxidansSubsp.denitrificans(Rüger and Tan) Comb. Nov.Microbiology and Immunology, 1998
- Achromobacter xylosoxidans Bacteremia: Report of Four Cases and Review of the LiteratureClinical Infectious Diseases, 1996
- Infection by Alcaligenes xylosoxidans subsp. xylosoxidans in Neutropenic PatientsOncology, 1996
- Bacteremia Due to Achromobacter xylosoxidans in Patients with CancerClinical Infectious Diseases, 1992